SIRION Biotech GmbH
SIRION Biotech is Europe's leading commercial supplier of viral vectors used for genetic cell modelling, gene target validation and gene therapy and vaccination studies.
Since beginning sales in 2007, SIRION’s mission has been to change the paradigm for viral vector supplies. It has the ability to custom modify and supply all common viral vector types (adenovirus, lentivirus and AAV) within a matter of weeks.Its manufacturing network allows dependable supply of virus titers and quantities from preclinical and animal research levels to clinical testing.
The company also offers a full range of complementing virus related services, from advanced virion modifications to multi-staged virus driven cell modelling.
Its technologies include the transformational RNAiONE™knockdown validation platform to complete this versatile portfolio.
Several of its next-level innovations are available for out licensing to industrial clients.
Viral vector services
SIRION’s core expertise lies in the customized design and generation of virus vectors for genetic engineering of mammalian cell systems. With its comprehensive portfolio, SIRION offers a suitable option for almost any in vitro and in vivo application. This maximizes researchers’ experimental freedom when designing cell based projects and ensures maintenance of high quality standards.
SIRION can supply all three of the most commonly used virus systems for gene manipulation:Adenovirus customization
Recombinant adenovirus particles (AVs) are the viral vector of choice for strong, transient gene over expression and–knockdown.
SIRION Biotech`s patented adenovirus generation system is based on bacterial artificial chromosome (BAC) technology allowing for custom AV generation in under five weeks. SIRION uses replication deficient E1/E3 deleted stereotype 5 recombinant AVs that comply with all official safety criteria. SIRION`s service allows for virtually any vector customization within a range of 7.5 kb.
SIRION AVs enable proficient cell type accessibility for highly efficient transduction of hard to transfect cells, even primary cells, without species limitations.Lentivirus customization
Lentiviruses provide researchers with an ideal method for fast, efficient and cost effective generation of stable cell models.
SIRION Biotech`s lentiviral vector technology allows for constitutive as well as inducible gene modification. It offers a reliable system for strong gene over expression and –knockdown, with custom cloning-to-virus delivery times in less than four weeks. Inducible LV constructs enable the experimenter to work with otherwise unattainable, cell toxic gene targets or shRNA sequences, adding to the range of potential applications of this vector system.
SIRION`s in house optimized LV vectors enable the generation of expression-homogeneous, stable cell models without the necessity to waste time on additional clonal selection steps post-transduction.AAV customization
Adeno-associated viruses (AAV) possess biological characteristics that make them one of the most promising avenues for in vivo application of viral vectors. They allow long-lasting gene over expression and-knockdown to assess phenotypic impact of a gene at the level of the living organism.
AAVs feature a lack of apparent pathogenicity, along with long-term gene expression in vivo of up to one year.
SIRION Biotech undertakes customized construction and manufacture of AAV serotypes 1-6 and1.2 in less than eight weeks, guaranteeing a minimum of 1-5 x10E12 viral particles. This range allows for tissue targeted expression control that is further increased by a selection of cell specific promoter strategies. The service enables the integration of virtually any desired expression construct within the vector’s cloning capacity of 4.5 kb. Inducible systems are in development.
SIRION’s highly purified and concentrated AAVs enable non-toxic in vivo gene delivery and comply with German BL-1 (S1) safety regulations, which are among the most stringent in the world.
SIRION Biotech offers additional services that complement their viral vector platform. These include advanced cell modeling services and shRNA validation methods (RNAiONETM). The flexible combination of all these service lines makes SIRION a valuable partner in preclinical target research and the development of clinical collaborations.Cell modeling
SIRION’s cell engineering services are used to develop custom cell models for industrial and academic clients.
SIRION ’s highly versatile collection of viral vector- and RNAi-strategies drive this sophisticated genetic engineering service platform, virtually free from cell type limitations. Clients can choose between different types of expression modalities: transient vs. stable, constitutive vs. inducible as well as moderate or strong expression levels with up to four genes expressed from one vector backbone (multicistronic vector design).
SIRION can also access a wide portfolio of fluorescent reporter genes and luciferases (Promega) to further increase the range of customization possibilities.
The strong flexibility of the SIRION cell modeling service enables clients to meet all of their specific experimental requirements and addresses the challenges of today’s research and development field.Knockdown technology
Knockdown (KD) studies are indispensable approaches to determine the role of a gene and hence to identify new gene targets for drug development in basic and clinical research.
While rational algorithm-based designed shRNA sequences have been successfully used to identify active shRNA sequences, KD efficiency of these sequences often lies under 70%. Residual gene expression in turn reduces the overall credibility of such experiments.
SIRION has developed its proprietary RNAiONE™ technology as a platform from which to identify shRNA sequences with a high gene silencing efficiency that often exceeds 90 %, giving KD experiments the necessary credibility. These results, in turn can be fully translated to SIRION`s viral vector platform and cell model generation services, making it the ideal tool for future KD cell models.Preclinical target research
With this wide array of services, SIRION Biotechfunctionsas a specialized service provider for preclinical target research. Its customized cell modelling tools, based on proprietary viral vectors and RNAi technologies, offer access to in-depth functional gene analysis, improved target identification, validation and compound screening to industrial and academic researchers, worldwide.VariCHECK™
Combining over expression and knockdown vector modalities SIRION offers custom RNAi control cell models (VariCHECK™) to confirm ON-target phenotypes in shRNA driven knockdown models.
VariCHECK™ also enables experimenters to switch from the expression of an endogenous gene to a mutant protein variant.This valuable tool can be used to research cellular processes associated with disease-causing mutations in protein kinase domains, growth receptors, oncogenes and other key regulatory proteins.SenCELL™
Identification of next generation active compounds is a critical step in drug compound discovery. SIRION’s SenCELL™ Sensor Cell Lines help researchers to concentrate on their experiments without the need for time-consuming cell line development.Clinical applications
SIRION Biotech brings innovative technologies into collaborations with high clinical relevance, ready to be spun out with specific data and new investors.Ad19a
The novel AV serotype Ad19a, the first openly accessible subtype D adenovirus, has been made possible by SIRION's BAC technology. This serotype provides a truealternative to Ad5 and Ad2serotypes, can transduce human-derived cells (myoblasts, myotubes and dendritic cells) and, with a low prevalence of pre-immunizationin the human population, carries great potential as a new vehicle for virus driven vaccinations.Cell modeling tools for cancer therapy
SIRION has developed next level technologies to provide breast cancer cell models to screen for novel compounds that help improve the effects of radiation therapy.
More recently, cell specific and non-toxic transduction elements, coined LentiTherapy™ have initiated first clinical collaborations in the context of CAR-T cell therapies.
History and structure
Dr. Christian Thirion founded SIRION Biotech while also leading a research team at the Neurology-focused Friedrich-Baur-Institute in Munich-Grosshadern. Dr. Thirion is SIRION’s Chief Technology Officer and an eminent authority on cellular analysis and modeling who has worked on cell modeling projects for more than 100 clients, critically shortening pre-clinical cycles in drug compound discovery.
SIRION is based at Martinsried, just outside Munich, with local representations in the USA, Japan, South Korea and Israel. Commercial arrangements range from fee-for-service over exclusive rights on single clones all the way to milestone and licensing arrangements. The SIRION business model has achieved consistent 70% annual revenue growth since 2007.
The company is privately owned and has over the years raised funds from government and private investors. SIRION maintains close connections with scientific collaborators at academic institutions across Germany as well as a wide network of alliance companies and distribution partners.Contact
To learn more about SIRION Biotech products and services and how they can assist your business, please contact the supplier directly.
- > New success for SIRION Biotech vaccination candidate Ad19a/64
- > SIRION Biotech’s new vaccination candidate successful in Ad5 pre-immunization in-vivo study
- > SIRION Biotech presenting advanced viral vectors and BOOSTER technology at ELRIG Drug Discovery ’16
- > SIRION Biotech pioneering work on lentiviral vectors recognized in prestigious new scientific volume
- > Customized adenoviral vectors (AVs)
- > SIRION Biotech expands business and ideas
- > SIRION Biotech announces preclinical vaccination success
- > Modifying iPS Cells With Lentivirus to build more robust disease models
- > ProVector™: Protecting production cells from problematic transgene expression
- > SIRION Biotech promote progress of novel breakthrough vaccines at BIO-Europe
- > SIRION Biotech bringing latest viral vector insights to ELRIG Drug Discovery ’15
- > Viral vector specialist SIRION Biotech heading to ECC2015 Vienna
- > Research confirms superiority of SIRION Biotech’s AAV vectors and Lentivirus strategies
- > SIRION Biotech launches operation in USA
- > SIRION Biotech Adenovirus Services
- > Webinar by Dr Carl J Christel for all your Virus Vector needs
- > SIRION demonstrates readiness to meet soaring viral vector demand
- > Sophisticated cell modeling by SIRION Biotech
- CRO, CMO, CRAMS & CDMO
- Clinical Trials & Studies
- Drug Discovery
- Laboratory Equipment & Services
- Manufacturing & Production
- Pre-Clinical Research
- Regulatory Affairs & Compliance